Related Experiment Videos
Concentrations of Ustekinumab During Induction Therapy Associate With Remission in Patients With Crohn's Disease
Ninon Soufflet1, Gilles Boschetti2, Xavier Roblin3
1Department of Gastroenterology, Lyon-Sud University Hospital, Hospices Civils de Lyon, Pierre Bénite, and University Claude Bernard Lyon 1, Lyon, France.
Abstract:
Ustekinumab is approved for treatment of Crohn's disease (CD).1,2 Few data are available to assess the usefulness of monitoring inflammatory biomarkers and therapeutic drug monitoring to predict response to ustekinumab. We conducted a prospective study to assess the relationships between these parameters and the clinical outcome at week 16 in active CD patients receiving ustekinumab.